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relieved pain in 83.3% of symptomatic patients (5/6). Five patients with 
separate metastatic pulmonary nodules showed multiple hematogenous 
lung metastases within 2 months follow up. However, multiple local 
control rates was 75% (3/4) in the primary lung cancer patients with ex-
trapulmonary metastatic lesions, and only one patient recurred as hema-
togenous lung metastases at 8 months follow up. The Grade II toxicities 
included skin reaction in 1 patient, and esophagitis in 2 patients. The 
main GIII toxicity was leucopenia in 2 patients. 
Conclusions: Helical tomotherapy was effective for symptom pallia-
tion by multiple local controls in lung cancer patients with multiple 
extrapulmonary metastatic diseases. However, patients with separate 
multiple pulmonary nodules showed no beneﬁt for tomotherapy.
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Background: We introduce a pulmonary cancer patient IMRT process, 
the radiotherapy it confronts to the possibility of the beam for the opti-
mization of plan and the use of direction, the VOD and dose restriction 
factor it evaluates with the place where it minimizes the dose which is 
used in the lung and the heart it evaluates the useful characteristic of 
the IMRT techniques which it uses. 
Methods: The tumor permeated to the mediastinum and during rela-
tively long time it did 5 person lung cancer patients where the error 
which is located small in the object. The patient immobilization devices 
to side overlook maintains the upper half of body and ﬁxes the location 
of the arm, the belt uses. Then it press the epigastrium, it was decreased 
moving internal organs due to a respiratory movement. The treatment 
plans, the beam number and direction used 5,7,9 portal (from 200 to 
160, equispaced ﬁeld), 4 portal (anterior, posterior, bilateral poste-
rior oblique ﬁeld) and an-isotropic 7, 9 portal (non-equispaced ﬁeld, 
arbitrary ﬁeld). The dose restriction is based on the reference and it set, 
appropriately, virtual organ used. So, we got the therapy plan result 
which had become optimization. The radiotherapy plans evaluated dose 
volume histogram (DVH), used a isodose curve and the dose-statistics. 
Specially, before and after setting up the virtual organ delineation and it 
analyzed a kindness data and it conﬁrmed the useful characteristic. 
Results: Methods of equispace 9 portal IMRT and non-equispace 7 
portal IMRT are good results within 20% by PVT dose homogeneity, 
mean lung dose and V20, V25. And getting same good result by setup 
the virtual organ delineation. Also, know the possibility of complement 
error during treatment by using clinical draw up lung cancer IMRT 
protocol.
Conclusions: We draw up the protocol, it will be able to use in lung 
cancer IMRT, and know the possibility of getting the optimization of 
treatment plans with set of the virtual organ delineation which is ap-
propriate and the irradiation plans. 
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Objective: The aim of this study is to compare the effectiveness of 
surgery with that of radiosurgery for patients with a single synchronous 
brain metastasis from successfully treated non-small cell lung cancer. 
Method: Between 1995 and 2002, ﬁfty-three patients underwent resec-
tion of both a primary non-small cell lung cancers and the associated 
single brain metastasis. There were 33 men and 20 women with a mean 
age of 57 years (range, 32-85 years). At the time of diagnosis,forty-two 
patients experienced lung cancer related symptoms, whereas 11 patients 
experienced brain metastases-related symptoms. Forty-two patients had 
ungone thoracic surgery ﬁrst, and 11 patients had undergone neurosur-
gery or radiosurgery ﬁrst. Pneumonectomy was performed in 9 out of 42 
patients (21.4%), lobectomies in 30 (71.4%), and wedge resection in 3 
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(7.2%). Forty-eight patients (90.5%) underwent complete lymphadenec-
tomy. 35 patients underwent brain metastasectomy. 18 underwent SRS. 
Results: There was no postoperative mortality and severe complica-
tions after either lung or brain surgery. Histology showed 34 adenocar-
cinomas, 16 squamous cell carcinomas, and 3 large cell lung cancers. 
15 patients (28.3%) had no evidence of lymph node mtastases (N0), 20 
patients (37.7%) had hilar metastases (N1), and 18 patients (34%) had 
mediastinal metastases (N2). The 1-,2-, 3- and 5-year overall survival 
rates were 49%,19%, 10%, and 5%, respectively. The corresponding 
data for neurosurgery group was 55%, 17%, 11%, and 6%, respectively. 
The median survival time was 13 months. For SRS group the corre-
sponding data were 44.8%, 20.9% 10.5%, and 2%, respectively. The 
median survival time was 14 months. The differences between the two 
groups were not signiﬁcant (p>0.05). In lymph node negative patients 
(N0), the overall 5-year survival rate was 10%, as compared with a 
1% survival rate in patients with lymph node metastases (N1-2). The 
difference was signiﬁcant (p<0.01). For adenocarcinomas, the 5-year 
survival rate was 5%. The correspondent data for squamous cell lung 
cancers was 3%. The difference was not signiﬁcant (p>0.05). 
Conclusion: Although the overall survival rate for patients who have 
brain metastases from NSCLC is poor, surgical resection or radiosur-
gery may prove beniﬁcial in a select group of patients with synchro-
nous brain metastases and lung cancer without lymph node metastases.
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Background: Postoperative radiation therapy (PORT) in non small cell 
lung cancer (NSCLC) remains controversial. However, involved-ﬁeld 
conformal (3D) RT has never been studied prospectively. In this study, 
we aim to assess the outcome of patients treated with involved-ﬁeld 3D 
PORT with or without chemotherapy in NSCLC.
Methods: From September 1996 to 2006, data from 75 patients treated 
with curative surgery and PORT for NSCLC were retrospectively 
analyzed. Median age was 58 years (range: 38-76). There were 5 
patients with stage I, 22 with stage II, and 48 with stage III disease. 
Pneumonectomy or lobectomy was realized in 24 (32%) and 51 (68%) 
patients, respectively. Mediastinal lymphadenectomy was performed in 
all patients. Chemotherapy was given in 15 (20%). All patients had 3D 
conformal planning. Median RT dose was 60 Gy, and CTV included 
bronchial stump and only positive nodal areas.
Results: All patients have completed full treatment. With a median 
follow-up of 55 months, 26 patients are alive without disease. Me-
dian overall survival time was 24 months, with survival rate of 35% 
at 5 years. The 5-year locoregional control and distant disease-free 
rates were 80% and 57%, respectively (Fig.1). Patients treated with 
pneumonectomy and those treated with at least 60-Gy PORT had better 
outcome (Fig.2). Grade 3 or more CTC v3.0 toxicity was observed only 
in 4 (5%) pts.
Conclusions: We conclude that involved-ﬁeld 3D conformal 60-Gy 
PORT improves locoregional control without increasing lethal toxicity. 
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Purpose: To identify clinical and dosimetric factors predicting the 
risk of radiation pneumonitis (RP) and to evaluate the value of these 
factors in patients treated by accelerated hypofractionated radiotherapy 
(AHRT) alone for non-small cell lung cancer.
Materials and Methods: Sixty-nine patients were treated with AHRT 
to median dose of 54 Gy (range, 45-60 Gy) in daily 3 Gy fractions 
over 4 weeks. Dose-volume histograms (DVH) were obtained based on 
the adjusted dose converted to biologically equivalent dose delivered 
with 2 Gy per fraction using alpha/beta ratio of 3 in linear quadratic 
model. Dosimetric parameters for total lung were obtained: mean lung 
dose (MLD), Vdose (percentage of total lung volume irradiated more 
than dose). Radiation pneumonitis (RP) was graded according to the 
Radiation Therapy Oncology Group (RTOG) Acute and Late Lung 
Morbidity Scoring Criteria. We evaluated clinical parameters (sex, age, 
performance status, weight loss, pre-RT FEV1, tumor location, stage, 
RT dose) and dosimetric parameters (MLD, V5-50 in increments of 5 
Gy) associated with the prediction of RP.
